What is KPV?
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
Mechanism of Action
MC1R and MC3R partial agonism; NF-κB nuclear translocation inhibition; direct intracellular uptake reducing pro-inflammatory cytokines (IL-1β, TNF-α, IL-8, IL-6); inhibition of caspase-1 and NLRP3 inflammasome activation
Target: MC1R, MC3R, NF-κB, NLRP3 inflammasome
Research Indications
Research shows modulation of immune cell activity and inflammatory response
May reduce systemic and localized inflammatory markers
Some evidence for improved pathogen defense mechanisms
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose | 250 mcg | 3x weekly | Subcutaneous injection |
| Maintenance Dose | 500 mcg | Weekly | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove KPV vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial effects and adaptation period. Monitor for any adverse reactions.
Week 2–4
Primary effects begin to manifest. Adjust dosing as recommended by your provider.
Week 4–8
Main therapeutic effects should be established. Assess progress with your provider.
Week 8+
Evaluate results and determine continuation, cycling, or dose adjustments.
Side Effects & Safety
- Injection site reactions (redness, bruising, mild pain)
- Potential for allergic reaction — discontinue if rash or hives occur
- Individual reactions vary — start at the lowest dose and monitor carefully
- Consult your healthcare provider before use and report any unusual symptoms
FDA Status & Regulatory Info
KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte stimulating hormone (α-MSH), retaining its potent anti-inflammatory properties without melanocortin receptor-dependent melanization effects. Research demonstrates significant potential for inflammatory bowel disease (IBD), Crohn's disease, skin inflammatory conditions, and wound healing. Oral formulations show promise for gut-specific delivery. Research only.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 54 users report
Positive 98% · Neutral 2% · Negative 0%
Most reported benefits
Dose distribution
Median: 200–400 mcg · Most common: 200–400 mcg
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 60 days · Based on 43 repeat reporters
Share Your Experience
Rate KPV in the PeptIQ app and help the community make informed decisions.
Research purposes only
This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.